Rational development of novel treatment regimens to improve the efficacy of estrogen therapy in anti-estrogen-resistant ER plus breast cancer

被引：0
|
作者：
Traphagen, Nicole A. [1 ]
Jiang, Amanda [2 ]
Hosford, Sarah R. [1 ]
Miller, Todd W. [1 ]
机构：
[1] Dartmouth Geisel Sch Med, Lebanon, NH USA
[2] Dartmouth Coll, Hanover, NH 03755 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-4359
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4359
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    Bronte, Giuseppe
    Rocca, Andrea
    Ravaioli, Sara
    Puccetti, Maurizio
    Tumedei, Maria Maddalena
    Scarpi, Emanuela
    Andreis, Daniele
    Maltoni, Roberta
    Sarti, Samanta
    Cecconetto, Lorenzo
    Pietri, Elisabetta
    De Simone, Valeria
    Asioli, Silvia
    Amadori, Dino
    Bravaccini, Sara
    BMC CANCER, 2018, 18
  • [42] Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    Giuseppe Bronte
    Andrea Rocca
    Sara Ravaioli
    Maurizio Puccetti
    Maria Maddalena Tumedei
    Emanuela Scarpi
    Daniele Andreis
    Roberta Maltoni
    Samanta Sarti
    Lorenzo Cecconetto
    Anna Fedeli
    Elisabetta Pietri
    Valeria De Simone
    Silvia Asioli
    Dino Amadori
    Sara Bravaccini
    BMC Cancer, 18
  • [43] Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer?
    Rocca, Andrea
    Bronte, Giuseppe
    Ravaioli, Sara
    Puccetti, Maurizio
    Tumedei, Maria Maddalena
    Scarpi, Emanuela
    Maltoni, Roberta
    Sarti, Samanta
    Cecconetto, Lorenzo
    Bedei, Lucia
    Fedeli, Anna
    Andreis, Daniele
    Pietri, Elisabetta
    Calistri, Daniele
    Amadori, Dino
    Bravaccini, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER plus breast cancer
    Dailey, Gabrielle P.
    Rabiola, Christopher A.
    Lei, Gangjun
    Wei, Junping
    Yang, Xiao-Yi
    Wang, Tao
    Liu, Cong-Xiao
    Gajda, Melissa
    Hobeika, Amy C.
    Summers, Amanda
    Marek, Robert D.
    Morse, Michael A.
    Lyerly, Herbert K.
    Crosby, Erika J.
    Hartman, Zachary C.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [45] Re: Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
    Archer, DF
    Bush, T
    Nachtigall, LE
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (23) : 1950 - 1951
  • [46] PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER plus ) breast cancer models
    Nardone, Agostina
    Goldstein, Amit
    Shea, Martin J.
    Mithchell, Tamika
    Fu, Xiaoyong
    De Angelis, Carmine
    Hu, Huizhong
    Xu, Xiaowei
    Rajendran, Mahitha
    O'Connor, Mark
    Locker, Gershon
    Hilsenbeck, Susan
    Osborne, Kent
    Schiff, Rachel
    CANCER RESEARCH, 2015, 75
  • [47] Enhancing immunogenicity in immunologically cold ER plus breast cancer using estrogen receptor blockade and radiation therapy
    Bates, Amber M.
    O'Leary, Kathleen A.
    Emma, Sarah
    Nystuen, Erin
    Sumiec, Elizabeth G.
    Schuler, Linda A.
    Morris, Zachary S.
    CANCER RESEARCH, 2020, 80 (16)
  • [48] Estrogen plus progestin therapy and breast cancer in recently postmenopausal women
    Prentice, Ross L.
    Chlebowski, Rowan T.
    Stefanick, Marcia L.
    Manson, JoAnn E.
    Pettinger, Mary
    Hendrix, Susan L.
    Hubbell, F. Allan
    Kooperberg, Charles
    Kuller, Lewis H.
    Lane, Dorothy S.
    McTiernan, Anne
    O'Sullivan, Mary Jo
    Rossouw, Jacques E.
    Anderson, Garnet L.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 167 (10) : 1207 - 1216
  • [49] Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER plus or to ER- disease?
    Landmann, Alessandra
    Farrugia, Daniel J.
    Diego, Emilia
    Soran, Atilla
    Johnson, Ronald
    Bonaventura, Marguerite
    Dabbs, David J.
    Clark, Beth
    Brufsky, Adam
    Davidson, Nancy E.
    Lembersky, Barry C.
    Jankowitz, Rachel Catherine
    Puhalla, Shannon
    Ahrendt, Gretchen M.
    McAuliffe, Priscilla F.
    Bhargava, Rohit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
    Datta, Jharna
    Willingham, Natalie
    Manouchehri, Jasmine M.
    Schnell, Patrick
    Sheth, Mirisha
    David, Joel J.
    Kassem, Mahmoud
    Wilson, Tyler A.
    Radomska, Hanna S.
    Coss, Christopher C.
    Bennett, Chad E.
    Ganju, Ramesh K.
    Sardesai, Sagar D.
    Lustberg, Maryam
    Ramaswamy, Bhuvaneswari
    Stover, Daniel G.
    Cherian, Mathew A.
    FRONTIERS IN ONCOLOGY, 2022, 12
12345